香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2025年半年度募集資金存放與實際使用情況的專項報告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券 ...

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the management of raised funds by Guangdong Marubi Biotechnology Co., Ltd. for the first half of 2025, highlighting the total amount raised, its usage, and the management practices in place to ensure compliance with regulations. Group 1: Fundraising Overview - The company raised a total of RMB 842,140,000.00 from the issuance of 41 million shares at RMB 20.54 per share, with net proceeds amounting to RMB 790,001,978.42 after deducting issuance costs of RMB 52,138,021.58 [1] - As of June 30, 2025, the total amount used from the raised funds was RMB 535,181,303.64, with a remaining balance of RMB 270,426,824.67 in the dedicated fundraising account [1][2] Group 2: Fund Management Practices - The company has established a dedicated fund management system in compliance with relevant regulations, including the opening of special accounts for fundraising and signing of tripartite supervision agreements with sponsors and banks [1] - The remaining balance in the fundraising account as of June 30, 2025, is distributed across various banks, with RMB 236,579,195.01 held in one account and RMB 25,918,241.87 in another [1] Group 3: Fund Usage and Projects - The company has not used idle funds for temporary working capital or to repay bank loans, nor has it changed the use of raised funds for ongoing or new projects [2][3] - The construction of the "Cosmetics Intelligent Manufacturing Factory" has been completed, but production line construction is still pending, with plans for future capacity and project arrangements based on market conditions [2][3] Group 4: Compliance and Reporting - The company has adhered to the fundraising management regulations and has not encountered any significant violations in the use of raised funds [2] - There are no changes in the implementation location or method of the fundraising projects, and no early investments or replacements have occurred [3]

证券代码：603209 证券简称：兴通股份 公告编号：2025-064 兴通海运股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》和《上海证券交易所上市公司自律监管指南第 1 号—— 公告格式》的规定，结合《兴通海运股份有限公司募集资金管理办法》（以下简 称"《募集资金管理办法》"），兴通海运股份有限公司（以下简称"公司"） 编制了《2025 年半年度募集资金存放与实际使用情况专项报告》，具体如下： 一、募集资金基本情况 （一）2022 年首次公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准兴通海运股份有限公司首次公开发行 股票的批复》（证监许可[2022]303 号）核准，公司向社会公众公开发行人民币 普通股股票（A 股）50,000,000 股，发行价格为每股 21.52 元。本次发行募集资 金总额为 1,076,000,000.00 元，扣除保荐承销费用、审计验资费用、律师费用、 用于本次发行的信息披 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 按照中国证监会《上市公司募集资金监管规则》、上海证券交易所颁布的《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》及相关格式指引等要 求，现将公司 2025 年半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 证券代码：601956 证券简称：东贝集团 公告编号：2025-035 湖北东贝机电集团股份有限公司 关于公司2025年半年度募集资金存放与实际使用情 况的专项报告 经中国证券监督管理委员会《关于核准湖北东贝机电集团股份有限公司非公 开发行股票的批复》（证监许可［2021］2940 号）核准，湖北东贝机电集团股 份有限公司（以下简称"公司"或"本公司"）非公开发行股票 100,000,000.00 股，每股面值人民币 1 元，每股发行价格为人民币 5.88 元，募集资金总额为 费（不含税）共计 10,179,245.28 元的出资款人民币 577,820,754.72 元，再扣 除其他与 ...

证券代码：688328 证券简称：深科达 公告编号：2025-041 深圳市深科达智能装备股份有限公司 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等相关法 律法规的规定及要求，深圳市深科达智能装备股份有限公司（以下简称"公司" 或"深科达"）编制了2025年半年度募集资金存放、管理与实际使用情况的专项 报告，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额及到账情况 经中国证券监督管理委员会出具的《关于同意深圳市深科达智能装备股份有 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕1235 号）同意，公司向不特定对象发行可转换公司债券 360 万张，每张面值为人民币 月 12 日已全部到位，并经大华会计师事务所以"大华验字[2022]000569 号"验 资报告验证确认。 （二）募集资金使用及结余情况 截至 2025 年 6 月 30 日，公 ...

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the management of raised funds by Sanxiang New Materials Co., Ltd. for the first half of 2025, detailing the amount raised, its usage, and the management practices in place to ensure compliance with regulatory requirements. Group 1: Fundraising Overview - The company raised a total of RMB 22,000.00 million through a non-public offering of 11,066,400 shares at RMB 19.88 per share, with a net amount of RMB 21,607.63 million after deducting issuance costs [1][2] - As of December 31, 2024, the cumulative direct investment of the raised funds was RMB 15,524.13 million, leaving an unused balance of RMB 6,313.13 million [2] Group 2: Fund Management Practices - The company has established a fundraising management system to ensure the proper management and usage of the raised funds, in compliance with relevant regulations [2][3] - Funds are stored in dedicated accounts with strict approval processes for usage, ensuring that the funds are used for their intended purposes [3][4] Group 3: Fund Usage and Status - As of June 30, 2025, the company had not utilized any idle funds for cash management or temporary liquidity support, and there were no changes in the investment projects funded by the raised capital [6][7] - The total amount of raised funds invested in projects was RMB 16,125.87 million, with an additional RMB 601.75 million invested in the current year [8] Group 4: Compliance and Reporting - The company has adhered to the disclosure requirements set forth by regulatory bodies, ensuring timely and accurate reporting of the fundraising and usage status [7][8] - There were no significant changes in the feasibility of the projects funded by the raised capital, and no adjustments to the usage of the funds were reported [8]

Fundraising Overview - The company raised a total of RMB 71,327.04 million from the issuance of 23.34 million shares at a price of RMB 30.56 per share, with a net amount of RMB 63,994.55 million after deducting issuance costs of RMB 7,332.49 million [1][2] - As of June 30, 2025, the remaining balance of unused raised funds is RMB 12,935.19 million, which includes RMB 235.19 million in the fundraising account and RMB 12,700.00 million in time deposits and financial products [2][3] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure the effective management and use of raised funds, including the establishment of dedicated bank accounts for fundraising [2][3] - The company signed tripartite and quadripartite supervision agreements with its subsidiaries and the sponsoring institution to clarify the rights and obligations of all parties involved [2][3] Fund Usage - The company has not used idle raised funds to temporarily supplement working capital during the reporting period [4][5] - The company has approved the use of up to RMB 16,000 million of idle raised funds for cash management, ensuring that it does not affect the normal progress of fundraising investment plans [5][6] - As of June 30, 2025, the company has invested RMB 12,700.00 million in various financial products, including transferable large-denomination certificates of deposit and structured deposits [5][6] Project Investment - The company has not made any early investments or replacements for fundraising investment projects during the reporting period [7] - The company has approved the use of part of the raised funds for new projects, including the development of a tumor companion diagnostic technology platform and a digital pathology and intelligent application development project, with an estimated investment of RMB 6,350.00 million [5][6] Remaining Funds - The company has a remaining balance of RMB 10,732.55 million in excess raised funds, which is not applicable for permanent working capital supplementation or loan repayment [6][7]

Summary of Key Points Core Viewpoint - The report details the fundraising and usage status of Hangzhou Lande Precision Machinery Co., Ltd. for the first half of 2025, highlighting the total amount raised, expenditures, and management of the funds [1]. Fundraising Basic Situation - The company raised a total of RMB 935.4 million by issuing 60 million shares at RMB 15.59 per share, with a net amount of RMB 861.23 million after deducting issuance costs of RMB 74.17 million [1]. - As of June 30, 2025, the detailed usage of the raised funds includes RMB 625.23 million for project investments, RMB 27.35 million for working capital, and RMB 3.82 million for fees, with a remaining balance of RMB 5.78 million in the special account [1][2]. Fundraising Management Situation - The company has established a fundraising management system to ensure the effective use of funds, including a tripartite supervision agreement with the sponsor and bank [1]. - As of June 30, 2025, the balance in the fundraising special account was RMB 65.12 million at CITIC Bank and RMB 29.48 million at Hangzhou Bank [2]. Actual Usage of Fundraising - The company did not use idle funds for temporary working capital or for cash management during the reporting period [2][3]. - The high-precision mechanical component production project was completed, with a remaining balance of RMB 54.86 million, of which RMB 49.08 million has been used to supplement working capital [2][3]. Changes in Fundraising Investment Projects - The company has made changes to its fundraising investment projects, including the transformation of the "annual production of 65,000 sets of high-precision mechanical components" project to the "high-precision mechanical component production construction project" [2][5]. - The company has not transferred or replaced any fundraising investment projects during the reporting period [2][5]. Issues in Fundraising Usage and Disclosure - There were no significant issues in the usage and disclosure of fundraising during the reporting period [2].

电力系统中高压控制及储 中国银行股份有限公 能设备关键零部件建设与 2025/5/13 司无锡太湖新城支行 无锡锡南科技股份有限公司 2025 年半年度募集资金存放与使用情况专项报告 无锡锡南科技股份有限公司 一、 募集资金基本情况 （一）实际募集资金金额和资金到位时间 经中国证券监督管理委员会《关于同意无锡锡南科技股份有限公司首次公开发行股票注 册的批复》（证监许可〔2023〕729 号）核准，并经深圳证券交易所同意，本公司由主承 销商中信证券股份有限公司于 2023 年 6 月 14 日向社会公众公开发行普通股（A 股）股票 止，本公司共募集资金 850,000,000.00 元，扣除发行费用 96,097,551.04 元（不含增值 税），募集资金净额 753,902,448.96 元。 截至 2023 年 6 月 20 日，本公司上述发行股票募集的资金已全部到位，业经大华会计 师事务所（特殊普通合伙）以"大华验字[2023]000367 号"验资报告验证确认。 （二）募集资金使用和结余情况 截至 2025 年 6 月 30 日，公司累计使用募集资金 485,843,333.22 元，其中：截至本报 告 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2025-029 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等有关规定，哈尔滨敷尔佳科技股 份有限公司（以下简称"公司"）现将公司 2025 年半年度募集资金实际存放与 使用情况专项说明如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2023]1157 号文核准，并经深圳证券 交易所同意，公司由主承销商中信证券股份有限公司于 2023 年 7 月 20 日向社会 公众公开发行普通股（A 股）股票 4,008.00 万股，每股面值 1 元，每股发行价 人民币 55.68 元。截至 2023 年 7 月 26 日止，公司共募集资金 2,231,654,400.00 元，扣除发行费用 159,889,838.58 元，募集资金净额 2,071,764,561.42 元。 截至 2023 年 7 月 26 日， ...